Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

Aurora Innovation, BYD, and Tempus AI are just three of Lingotto Innovation’s holdings with explosive growth potential.

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Today, Zacks Investment Ideas feature highlights Palantir PLTR, Tempus AI TEM and Comfort Systems USA FIX. These 3 AI-Relate ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy ...

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

A technology company specializing in the application of artificial intelligence to advance precision medicine and patient ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

In its first-quarter 2025 investor letter, Baron Discovery Fund highlighted stocks such as Tempus AI, Inc. (NASDAQ:TEM) . Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company.